This company has been acquired
Dividendos de F-star Therapeutics
Dividendo controles de criterios 0/6
Información clave
n/a
Rentabilidad por dividendo
n/a
Ratio de pago
| Rentabilidad media de la industria | 2.8% |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Beneficios por acción | -US$2.04 |
| Rentabilidad por dividendo prevista a 3 años | n/a |
Últimas actualizaciones de dividendos
No hay actualizaciones
Recent updates
F-star Therapeutics: Running Into A National Security Roadblock
Sep 22F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma sale
Sep 15F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
Jul 29F-star enters license deal with Takeda for a cancer immune therapy antibody
Jul 20Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) Revenues
May 18
US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest Results
Mar 17These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS Forecasts
Mar 16F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
Jan 27F-star Therapeutics under pressure on pricing $65M stock offering
May 07Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks Like
Mar 17Merck KGaA discloses 5.4% stake in F-star Therapeutics
Feb 02Dosing underway in early-stage study of F-star's FS120 in cancer
Dec 03Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: Insufficient data to determine if FSTX's dividends per share have been stable in the past.
Dividendo creciente: Insufficient data to determine if FSTX's dividend payments have been increasing.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de F-star Therapeutics vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (FSTX) | n/a |
| Suelo de mercado 25% (US) | 1.5% |
| Techo de mercado 25% (US) | 4.6% |
| Media de la industria (Biotechs) | 2.8% |
| Previsión de analistas en 3 años (FSTX) | n/a |
Dividendo destacado: Unable to evaluate FSTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Alto dividendo: Unable to evaluate FSTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Pago de beneficios a los accionistas
Cobertura de los beneficios: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: Unable to calculate sustainability of dividends as FSTX has not reported any payouts.